Anti-TNFα Treatment After Surgical Resection for Crohnʼs Disease Is Effective Despite Previous Pharmacodynamic Failure-Reference-Cited by-同舟云学术

Anti-TNFα Treatment After Surgical Resection for Crohnʼs Disease Is Effective Despite Previous Pharmacodynamic Failure

Published:2017-05 Issue:5 Volume:23 Page:791-797
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Assa Amit,Bronsky Jiri,Kolho Kaija-Leena,Zarubova Kristyna,de Meij Tim,Ledder Oren,Sladek Margaret,van Biervliet Stephanie,Strisciuglio Caterina,Shamir Raanan

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference29 articles.

1. Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

2. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

3. Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms

4. Antibodies to Infliximab and Risk of Infusion Reactions in Patients With Inflammatory Bowel Disease

5. Review article: loss of response to anti-TNF treatments in Crohn’s disease

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preventing Recurrence of Crohn’s Disease Post-Ileocaecal Surgery in Paediatric Patients: A Therapy Guide Based on Systematic Review of the Evidence;Pediatric Drugs;2024-08-31

2. Management of Post-Operative Crohn’s Disease: Knowns and Unknowns;Journal of Clinical Medicine;2024-04-16

3. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease;Drugs;2023-07-28

4. Which Patients Benefit from Biologic Agents to Prevent Disease Recurrence After Resection in Crohn’s Disease?;Difficult Decisions in Surgery: An Evidence-Based Approach;2023

5. A Single-Center Study of Long-Term Effectiveness of Vedolizumab in Anti-TNF Refractory Pediatric Inflammatory Bowel Disease;JPGN Reports;2022-12-27